Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

Cancer Immunology Immunotherapy

Volumn 37, Issue 4, 1993, Pages 255-263

  Lewis, Gail D ^a   Figari, Irene ^a   Fendly, Brian ^a   Lee Wong, Wai ^a   Carter, Paul ^a   Gorman, Cori ^a   Shepard, H Michael ^a  

^a GENENTECH INC   (United States)

Author keywords

Cytotoxicity; Growth inhibition; Monoclonal antibodies; p185HER2

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CELL LINE; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTO ONCOGENE; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0027375130     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF01518520     Document Type: Article

References (72)

1. Expression of oncogenes in thyroid tumors: coexpression of c- erbB2/neu and c- erbB
2. The product of the human c- erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity
3. Tamoxifen resistance associated with p185HER2 overexpression in human breast cancer cells transfected with HER2/neu
4. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
5. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage discase
6. Correlation of c- erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
7. In vivo amplification and rearrangement of c- myc oncogene in human breast tumors
8. Oncogene alterations in endometrial cancer
9. Amplification of N- myc in untreated human neuroblastomas correlates with advanced disease stage
10. Cytogenetics and DNA amplification in colorectal cancers
11. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
12. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
13. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo
14. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic antitumor effects in vivo
15. Characterization of monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
16. Epidermal growth factor receptor of A431 cells. Characterization of a monoclonal anti-receptor antibody noncompetitive agonist of epidermal growth factor action
17. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers
18. Localization of a novel v- erbB-related gene, c- erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line
19. Overexpression of either c- myc or c- erbB-2/neu protooncogenes in human breast carcinomas: correlation with poor prognosis
20. Structure and expression of c- erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance
21. Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy
22. Amplified expression of the HER2/erbB-2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells
23. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
24. Overexpression of the c- erbB-2 protein in human breast tumor cell lines
25. myc family DNA amplification in small cell lung cancer patients tumors and corresponding cell lines
26. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
27. Expression of erbB2 in human gastric carcinomas: relationship between p185erbB2 expression and gene amplification
28. p185neu expression in human lung adenocarcinomas predicts shortened survival
29. Amplification of a novel v- erbB-related gene in a human mammary carcinoma
30. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
31. Isolation and characterization of ERBB3, a third member of the “ERBB”/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors
32. Expression of the N- myc gene in primary retinoblastoma
33. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human tumors of glial origin
34. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokineactivated killer cells: correlation with expression ofHER2/neu oncogenes
35. Amplification and expression of the c- myc oncogene in human lung cancer cell lines
36. Chimeric mousehuman IgG1 antibody that can mediate lysis of cancer cells
37. Amplified and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells
38. Expression of C-ERBB-2 gene product in urinary bladder cancer
39. Amplification, overexpression and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas
40. Epidermal growth factor receptors in human breast cancer
41. Reshaping human antibodies for therapy
42. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma
43. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
44. The neu oncogene: an erbB-related gene encoding a 185,000- Mr tumor antigen
45. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
46. Differential expression of the c- erbB-2 gene in human small cell and non-small cell lung cancer
47. Association of multiple copies of the N- myc oncogene with rapid progression of neuroblastomas
48. A v- erbB-related protooncogene, c- erbB-2 is distinct from the c- erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma
49. The significance of oncogene amplification in primary breast cancer
50. The development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
51. Human immune response to multiple injections of murine monoclonal IgG
52. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
53. Expression of cellular oncogenes in human malignancies
54. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
55. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
56. p185, a product of the neu protooncogene, is a receptorlike protein associated with tyrosine kinase activity
57. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues
58. HER2/neu oncogene protein and prognosis in breast cancer
59. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
60. Amplification of the neu (c- erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c- erbA oncogene
61. Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
62. Overexpression of the c- erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification
63. ras oncogenes and the molecular mechanisms of carcinogenesis
64. Expression of c-erbB-2 in human pancreatic adenocarcinomas
65. Expression of c- erbB-2 oncoprotein: a prognostic indicator in human breast cancer
66. High incidence of amplification of epidermal growth factor receptor gene in human squamous carcinoma cell line
67. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c- erb) in human brain tumors
68. Enhanced expression of c- myc and epidermal growth factor receptor (c- erbB1) genes in primary human renal cancer
69. Genetic alterations of the c- erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v- erbA homologue
70. Evaluation of immunorcactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer
71. Association of multiple copies of the c- erbB-2 oncogene with spread of breast cancer